Physician profile
James Strobel
NPI 1730187998
$3,117.20
in general payments reported to CMS, 2019-2025
21 companies · $563 in 2025
The $563 reported for 2025 was less than what a typical Gastroenterology (Internal Medicine) provider received nationally (typical 2025 total: $636).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $286 · 2020: $156 · 2021: $556 · 2022: $594 · 2023: $376 · 2024: $587 · 2025: $563.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,526.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,526.09 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Biotech, INC. | $965.06 | 2019-2025 | Stelara, Tremfya |
| Abbvie INC. | $920.03 | 2019-2025 | Linzess, Creon, Viberzi |
| Phathom Pharmaceuticals, INC. | $226.44 | 2024-2025 | Voquezna |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $197.02 | 2019-2021 | |
| Takeda Pharmaceuticals U.S.A., INC. | $110.15 | 2019-2023 | Entyvio |
| Regeneron Healthcare Solutions, INC. | $83.80 | 2024-2025 | Dupixent |
| Medtronic USA, INC. | $83.16 | 2019-2020 | |
| Boston Scientific Corporation | $76.66 | 2022 | |
| Pfizer INC. | $75.04 | 2019-2025 | |
| Genzyme Corporation | $71.11 | 2022-2025 | |
| Medtronic, INC. | $70.28 | 2025 | Interstim |
| Gilead Sciences, INC. | $45.77 | 2025 | Livdelzi |
| Daiichi Sankyo INC. | $36.22 | 2022-2025 | Injectafer |
| Merck Sharp & Dohme LLC | $32.42 | 2021-2023 | Dificid |
| Janssen Scientific Affairs, LLC | $29.47 | 2024 | Stelara |
Show all 21 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ardelyx, INC. | $27.90 | 2023-2024 | Ibsrela |
| Madrigal Pharmaceuticals | $17.46 | 2025 | Rezdiffra |
| Ucb, INC. | $13.89 | 2019 | |
| Organon LLC | $12.18 | 2021 | |
| Ironwood Pharmaceuticals, INC | $11.58 | 2021 | |
| Endogastric Solutions, INC | $11.56 | 2023 | Esophyx |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw James Strobel listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.